<DOC>
	<DOC>NCT01015196</DOC>
	<brief_summary>First randomization: After inclusion Use of Daunorubicin (arm D) or Idarubicin (arm I) as anthracyclin during all courses of chemotherapy (induction, consolidation courses before ASCT) Second randomization: After achieving 1st CR: all patients received non intensive consolidation course Familial HLA typing required for all patients Patients with HLA-identical sibling: Patients with very good prognostic factors (CBF leukemias, WBC &lt; 30 giga/l at diagnosis, 1st CR after one induction course) = arm C: no allogeneic stem cell transplantation in 1st CR; received 2 more courses of intensive consolidation chemotherapy All others patients received an allogeneic transplant For patients aged less than 51 = arm M: upfront myeloablative conditioning regimen For patients aged over 51 and less than 61= arm m: intensive chemotherapy consolidation course.</brief_summary>
	<brief_title>Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Patients aged 15 to 60 years Diagnosis untreated AML (FAB 0 to 2, 4 to 7): more than 20% marrow blasts according to WHO classification Signed informed consent required AML3 subtype Previous diagnosis of myelodysplastic syndrome (MDS) or myeloproliferative disease; patients with previous chemotherapy or radiotherapy were eligible if they had no previous diagnosis of MDS Isolated extramedullary disease Inadequate performance status (≥ 3), cardiac function (LVEF &lt; 40%, severe arythmia or unstable coronary disease), renal function (creatininine &gt; 150 µmol/l), liver functional tests (bilirubin &gt; 35 µmol/l, liver enzymes &gt; 4 times normal values); life expectancy &lt; 3 months Informed consent refusal</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>acute myeloid leukemia in first complete remission</keyword>
</DOC>